Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › GA › Stockbridge › NPI 1003221904
Lab

National Premier Laboratories INC

National Premier Laboratories INC was paid $3.38M by Medicaid between Jan 2018 and Oct 2019, across 104 billing codes. Its largest line is 81298, — 12% of everything it billed.

33Billing provider infoNATIONAL PREMIER LABORATORIES INC
STOCKBRIDGE, GA 30281
33aNPI1003221904assigned 06/30/2014
28Total paid$3.38M
24GClaims44,728
24DCodes billed104
24AFirst – last monthJan 2018 – Oct 2019
Compared with peers

Next to other Clinical Medical Laboratory providers in Georgia

Rank by total paid#16 of 66
Median peer was paid$178K
This provider vs. median19×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$500K$1.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201826,684$1.65M
201918,044$1.73M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
81298 12% 601 504 $408K
81292 11% 599 503 $368K
81321 11% 597 499 $362K
81317 11% 562 481 $358K
81201 10% 483 418 $345K
81295 7.0% 585 490 $238K
81406 6.8% 1,053 502 $229K
81405 5.9% 1,489 503 $198K
81404 4.9% 1,049 501 $167K
81403 3.0% 548 467 $102K
81401 2.4% 1,364 1,225 $80K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.0% 2,936 2,536 $67K
92 more codes
81408 1.6% 606 $54K
81241 1.6% 1,320 $53K
81162 1.4% 548 $46K
81240 1.3% 1,319 $45K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1.1% 885 $37K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 516 $24K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 735 $24K
81479 Unlisted molecular pathology procedure <1% 5,242 $22K
81226 <1% 1,444 $11K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 568 $10K
81225 <1% 1,441 $9K
81402 <1% 438 $7K
81328 <1% 1,318 $6K
81230 <1% 1,449 $6K
81231 <1% 1,354 $6K
81227 <1% 1,435 $4K
80361 <1% 284 $3K
80349 <1% 319 $3K
80365 <1% 325 $3K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 235 $3K
80373 <1% 300 $3K
83992 <1% 248 $3K
80348 <1% 287 $3K
80354 <1% 283 $3K
80358 <1% 282 $3K
80372 <1% 283 $3K
80367 <1% 282 $3K
81291 <1% 1,182 $3K
80364 <1% 220 $3K
81242 <1% 43 $3K
80356 <1% 267 $3K
80353 <1% 250 $3K
80359 <1% 248 $3K
80347 <1% 186 $2K
80357 <1% 195 $2K
80371 <1% 159 $2K
80355 <1% 161 $2K
80360 <1% 138 $2K
80366 <1% 145 $2K
80321 <1% 136 $2K
80370 <1% 134 $2K
80352 <1% 132 $2K
81355 <1% 1,304 $2K
80325 <1% 120 $2K
80338 <1% 119 $2K
80345 <1% 121 $2K
80333 <1% 119 $2K
80342 <1% 116 $2K
80061 Lipid panel <1% 240 $2K
80368 <1% 99 $1K
82607 <1% 214 $1K
83036 Hemoglobin; glycosylated (A1C) <1% 251 $1K
86141 <1% 162 $1K
80375 <1% 76 $1K
80050 General health panel <1% 131 $933.63
80376 <1% 78 $921.28
82746 <1% 150 $920.54
80323 <1% 78 $910.72
80337 <1% 56 $734.44
80335 <1% 47 $646.71
84439 <1% 154 $632.80
84146 <1% 39 $505.58
83540 <1% 146 $421.11
80053 Comprehensive metabolic panel <1% 64 $326.09
81400 <1% 288 $316.92
80076 <1% 35 $260.23
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 63 $249.16
84481 <1% 81 $247.32
82626 <1% 69 $222.42
84443 Thyroid stimulating hormone (TSH) <1% 46 $190.05
84403 <1% 69 $157.97
82533 <1% 69 $143.47
84270 <1% 56 $140.25
84144 <1% 68 $137.37
83001 <1% 67 $127.86
83002 <1% 67 $127.38
83090 <1% 68 $107.41
82670 <1% 79 $105.94
83698 <1% 12 $102.12
86376 <1% 51 $100.07
82728 <1% 67 $93.82
83695 <1% 41 $89.04
83525 <1% 42 $88.53
84466 <1% 41 $85.51
84080 <1% 14 $61.46
83735 <1% 69 $42.74
85651 <1% 29 $16.32
80362 0% 39 $0.00
80346 0% 64 $0.00
84436 0% 15 $0.00
83550 0% 13 $0.00
84480 0% 14 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBERINHOUT, RANDALL (PRESIDENT)